Dr. Woyach on Ibrutinib Regimens in Frontline CLL

Video

In Partnership With:

Jennifer Woyach, MD, discusses the findings of the ALLIANCE AO41202 and ECOG-ACRIN E1912 trials in the frontline treatment for patients with chronic lymphocytic leukemia.

Jennifer Woyach, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center—James, discusses the findings of the ALLIANCE AO41202 and ECOG-ACRIN E1912 trials in the frontline treatment for patients with chronic lymphocytic leukemia (CLL).

Both of these trials compared ibrutinib (Imbruvica) alone or in combination with another agent with standard chemotherapy as frontline treatment in patients with CLL, explains Woyach. The ECOG-ACRIN E1912 trial compared ibrutinib plus rituximab (Rituxan) with fludarabine, cyclophosphamide, and rituximab (FCR), for example. That study showed a significant advantage in both progression-free survival and overall survival with ibrutinib/rituximab versus FCR, according to updates presented at the 2019 ASH Annual Meeting.

Meanwhile, there is not much difference between regimens in the very good genomic-risk patients, including those with IGHV-mutated disease, says Woyach. The 2 treatments are fairly similar at this follow-up, though mostly because those patients do very well; no one has relapsed on either arm, concludes Woyach.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,